We are living in a stressful world. Anxiety disorders are the most common mental illness in the U.S., affecting 40 million adults in the United States age 18 and older, or 18.1% of the population every year, according to the Anxiety and Depression Association of America (ADAA). Two in three Americans say they are extremely or somewhat anxious about their safety, finances, health and relationships, according to a 2019 survey from American Psychiatric Association (APA).
Polls like these provide clues for the causes of anxiety. But the numbers also point to a need for better treatments. Currently, treatment options for General Anxiety Disorders (GAD) primarily fall into two categories: psychotherapy and medication, and sometimes a combination of both. But factors ranging from cost to mental illness stigma make many GAD suffers unable to access treatment. ADAA estimates only 36.9% of those suffering receive treatment.
Niraxx Light Therapeutics Co-Founder Paolo Cassano, MD, PhD believes light may provide a safe, natural solution to chronic anxiety. Here’s an excerpt from his Medium article published earlier this month. He is also assistant professor of psychiatry at Harvard Medical School and Director of Photobiomodulation at the Massachusetts General Hospital (MGH) Neuropsychiatry.
Dr. Cassano says new findings show new applications for the therapeutic use pf transcranial photobiomodulation (t-PBM), which uses near infrared light to stimulate the brain.
Preliminary studies have suggested near-infrared light’s potential as an antidepressant and anxiolytic — not to mention its ability to improve our overall cognitive function and performance.
Here at Niraxx, our goal is to develop one of its kind t-PBM e-Textile wearable that has the capability to monitor brain state, provide live feedback and suggest dosage adjustments. We envision a personalized predictive model created just for you. We thank you for joining us on this exciting journey. Welcome to the Niraxx Life community!